Clinical Trials Logo

CTCL clinical trials

View clinical trials related to CTCL.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05879458 Recruiting - Mycosis Fungoides Clinical Trials

Ritlecitinib in CTCL

Start date: May 17, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to evaluate the effectiveness and safety of Ritlecitinib in skin and blood in persons with Cutaneous T-Cell Lymphoma (CTCL). CTCL is a rare type of cancer that starts in the white blood cells and eventually can result in rashes or tumors in the skin. This study includes a 24 week Treatment Period and a 24 week Follow-up Period. This study will involve physical examinations, visual assessments, laboratory tests, PET-CT scans, electrocardiograms, photographs of your skin, skin biopsies, and hearing tests.

NCT ID: NCT04087629 Recruiting - CTCL Clinical Trials

StrataCTX® as a Steroid Sparing Device

Start date: July 7, 2021
Phase: N/A
Study type: Interventional

The purpose is to determine if StrataCTX® can be used as a steroid sparing agent for the treatment of cutaneous reactions related to, cutaneous T Cell lymphoma (CTCL) and chemotherapy/immunotherapy treatments than the current standard treatment - topical steroids - in people who are receiving treatment for CTCL, or chemotherapy/immunotherapy for solid/hematologic malignancies. Subjects will have CTCL and are being treated with topical steroids, or being treated with chemotherapy/immunotherapy for another condition and have had cutaneous reactions that have warranted initiation of topical steroids.

NCT ID: NCT03240211 Recruiting - PTCL Clinical Trials

Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

Start date: February 2, 2022
Phase: Phase 1
Study type: Interventional

This is an international, multicenter, multi-arm, phase Ib, model-based dose-escalation study. The primary objectives of the study in each arm is to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), dose limiting toxicities (DLTs) and to evaluate the clinical efficacy at the MTD of various combinations of pembrolizumab, pralatrexate and decitabine.